Allarity cites patent awards, CLIA lab certification to advance stenoparib DRP companion diagnostic

Allarity Therapeutics, Inc.

Allarity says recent patent awards plus CLIA certification of its in-house lab let it retain sole control of the stenoparib-DRP test as a companion diagnostic.
Stenoparib-DRP comprises a 414-gene expression signature including genes tied to WNT pathway activity; DRP tests have been developed for dozens of cancer therapies.
At AACR 2026, an exploratory analysis of a prior Phase 2 cohort of advanced ovarian cancer patients on twice-daily stenoparib linked higher pretreatment DRP scores to longer overall survival.
CEO Thomas Jensen said the DRP-survival association helps inform the path toward FDA approval; stenoparib remains the principal development focus.
No financial results, patient counts, partnership terms or pivotal-trial timeline were disclosed in the update.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.